CI

At a glance

ClinicalIndex Comparison Record
Phase 3Active· 494 enrolled
Drug / intervention
Belantamab mafodotin +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04246047
NCT04246047Phase 3Active
CompareCT.gov

DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma

GlaxoSmithKline·interventional·Posted Jan 29, 2020·Updated Apr 23, 2026

In Brief

A Phase 3 clinical trial evaluating Belantamab mafodotin, Daratumumab, and 2 other interventions for Multiple Myeloma. Active but no longer recruiting, targeting 494 participants across 69 sites in 13 countries.

Detailed Summary

This is a Phase 3, randomized, open-label study designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone (Arm A) versus daratumumab in combination with bortezomib/dexamethasone (Arm B) in the participants with relapsed recurrent multiple myeloma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesAustralia, Belgium, China, Greece, Israel, Italy, Japan, Netherlands, Poland, Russia, South Korea, Spain, United States
Collaborators--

Timeline

Phase 3Active
202020212022202320242025202620272028
First PostedJan 29, 2020
Enrollment StartMay 7, 2020
Primary CompletionOct 2, 2023
Study CompletionJun 30, 2028
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 6.4 years ago

Interventions

Belantamab mafodotindrug

Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate

Daratumumabdrug

Anti-cluster of differentiation 38 \[CD-38\] monoclonal antibody

Bortezomibdrug

Proteasome Inhibitor

Dexamethasonedrug

Synthetic glucocorticoid with anti-tumor activity